Overcoming Inertia to Tame the Red Devil∗

Overcoming Inertia to Tame the Red Devil∗

Bibliographic Details
Main Author:	Christine E. Simmons, MD, MSc, FRCPC
Format:	Article
Language:	English
Published:	Elsevier 2019-09-01
Series:	JACC. CardioOncology
Subjects:	anthracyclines breast cancer cardioprotection dexrazoxane heart failure
Online Access:	http://www.sciencedirect.com/science/article/pii/S266608731930033X

Similar Items

Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series
by: Sarju Ganatra, et al.
Published: (2019-01-01)

Anthracycline-Induced Cardiotoxicity
by: Radomír Hrdina, et al.
Published: (2000-01-01)

Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer
by: Ariane V.S. Macedo, MD, MSc, et al.
Published: (2019-09-01)

Dexrazoxane in anthracycline cardiotoxicity
by: Abhijit S Nair
Published: (2017-01-01)

Can Dexrazoxane and Carvedilol prevent Doxorubicin-induced nephrotoxicity?
by: Szponar Jaroslaw, et al.
Published: (2024-12-01)

Safety Evaluation of the Combination with Dexrazoxane and Anthracyclines: A Disproportionality Analysis Based on the Food and Drug Administration Adverse Event Reporting System Database
by: Danyi Liu, et al.
Published: (2024-12-01)

Treatment of anthracycline extravasation from centrally inserted venous catheters
by: Seppo W. Langer
Published: (2011-12-01)

Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective
by: Sarah Dewilde, et al.
Published: (2020-02-01)

Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy
by: Muthiah Vaduganathan, MD, MPH, et al.
Published: (2019-09-01)

Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors
by: Sonu S. Varghese, et al.
Published: (2021-10-01)

Early detection of myocardial changes with and without dexrazoxane using serial magnetic resonance imaging in a pre-clinical mouse model
by: Cory V. Noel, et al.
Published: (2021-06-01)

Anthracycline-induced cardiotoxicity – primary preventive options. An overview
by: S. Slavcheva
Published: (2024-05-01)

Challenges in the implementation of cardio-oncology trials: lessons learnt from investigating statins in the prevention of anthracycline cardiotoxicity
by: John Lee, et al.
Published: (2024-12-01)

Cardioprotective effect of crocin in patients with breast cancer receiving anthracycline-based chemotherapy: A randomized, double-blind, placebo-controlled study
by: Xinye Li, et al.
Published: (2025-03-01)

The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity
by: Lori M. Minasian, MD, et al.
Published: (2019-09-01)

Rationale and design of the Children's Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy
by: Kasey J. Leger, et al.
Published: (2023-12-01)

Cardioprotective potential of botanical agents against anthracycline-induced cardiotoxicity
by: Parisa Firoozbakhsh, et al.
Published: (2024-05-01)

Acute Heart Failure 29 Years After Treatment for Childhood Cancer
by: Massimiliano Camilli, MD, et al.
Published: (2020-06-01)

Cardioprotection From Cardiotoxicity
by: Guilherme H. Oliveira, MD, MBA
Published: (2019-09-01)

Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane
by: Marijke Linschoten, et al.
Published: (2025-01-01)

Echocardiographic strategy for early detection of cardiotoxicity of doxorubicin: a prospective observational study
by: Diogo Pereira Santos Sampaio, et al.
Published: (2022-10-01)

Effect of standard low-dose anthracycline chemotherapy on late congestive heart failure in breast cancer survivors aged between 50 and 59 at diagnosis: A nationwide study
by: Il Yong Chung, et al.
Published: (2020-10-01)

CARDIOVASCULAR COMPLICATIONS CAUSED BY CHEMOTHERAPY AND TARGETED AGENTS
by: L. V. Bolotina, et al.
Published: (2016-01-01)

Terapêutica citoprotetora em pacientes tratados com quimio e/ou radioterapia anti neoplásica
by: Cármino A. Souza, et al.
Published: (2000-08-01)

Effects of Semaglutide in Doxorubicin-Induced Cardiac Toxicity in Wistar Albino Rats
by: HamaSalih RM
Published: (2024-06-01)

Pyridoxamine Limits Cardiac Dysfunction in a Rat Model of Doxorubicin-Induced Cardiotoxicity
by: Sibren Haesen, et al.
Published: (2024-01-01)

CardioMEMS-Guided CAR T Cell Therapy for Lymphoma in a Patient With Anthracycline-Induced Cardiomyopathy
by: Anthony J. Kanelidis, MD, et al.
Published: (2020-09-01)

Anthracycline-induced cardiotoxicity and senescence
by: Laura K. Booth, et al.
Published: (2022-11-01)

RISK FACTORS AND INCIDENCE OF MYOCARDIAL DAMAGE IN PATIENTS WITH HEMOBLASTOSIS RECEIVING ANTHRACYCLIN ANTIBIOTICS
by: N. T. Vatutin, et al.
Published: (2017-10-01)

High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity
by: George E. G. Kluck, et al.
Published: (2020-04-01)

Protective Role of Enalapril in Anthracycline-Induced Cardiotoxicity: A Systematic Review
by: Yili Zhang, et al.
Published: (2020-05-01)

In vitro to clinical translation of combinatorial effects of doxorubicin and dexrazoxane in breast cancer: a mechanism-based pharmacokinetic/pharmacodynamic modeling approach
by: Hardik Mody, et al.
Published: (2023-10-01)

Função sistólica do ventrículo esquerdo pela ecocardiografia em crianças e adolescentes com osteossarcoma tratados com doxorrubicina com e sem dexrazoxane Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane
by: Ranulfo Pinheiro de Matos Neto, et al.
Published: (2006-12-01)

Comprehensive Analysis of Transcriptomics and Genetic Alterations Identifies Potential Mechanisms Underlying Anthracycline Therapy Resistance in Breast Cancer
by: Zihao Liu, et al.
Published: (2022-12-01)

Treatment related acute promyelocytic leukemia (t-APML) in breast cancer survivor treated with anthracycline based chemotherapy: rare case report
by: Irappa Madabhavi, et al.
Published: (2016-02-01)

An Exploration of Heart Failure Risk in Breast Cancer Patients Receiving Anthracyclines with or without Trastuzumab in Thailand: A Retrospective Study
by: Jukapun Yoodee, et al.
Published: (2021-08-01)

Deciphering the cardioprotective effects of statins in anthracycline-related cardiac dysfunction: A systematic review and meta-analysis
by: Mubashar Karamat, et al.
Published: (2024-12-01)

Effects of sacubitril/valsartan in patients with cancer therapy-related heart failure
by: Marina V. Vitsenya, et al.
Published: (2023-09-01)

Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
by: Alexandros Briasoulis, et al.
Published: (2022-02-01)

In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521—A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics
by: Marek Jamrozik, et al.
Published: (2023-04-01)